Teva and Alvotech are introducing Selarsdi at an 85% discount off the reference product Stelara. Selarsdi is available as a subcutaneous injection and for intravenous infusion.

Teva and its partner Alvotech on Friday followed Amgen in launching a biosimilar to J&J's blockbuster immunosuppressive ...

Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Teva Pharmaceuticals and Alvotech said on Friday they have launched a biosimilar to Johnson & Johnson's autoimmune drug ...

The health sector is facing significant changes, with the FDA restricting language, New York suing e-cigarette makers, AstraZeneca expanding in China, Eli Lilly stockpiling weight-loss drugs, Teva and ...

The European Commission (EC) has approved Biocon Biologics’ Yesintek, an ustekinumab biosimilar referencing Johnson & Johnson’s Stelara, to treat multiple inflammatory diseases.

Teva Pharmaceuticals and Alvotech said on Friday they have launched a biosimilar to Johnson & Johnson's autoimmune drug Stelara in the United States. Selarsdi, like Stelara, is approved for the ...

Teva (TEVA) stock and Alvotech (ALVO) stock in focus as duo launches Selarsdi, a biosimilar to J&J's (JNJ) Stelara after a ...

Teva Pharmaceuticals (TEVA) and Alvotech (ALVO) announced the availability of SELARSDI injection in the U.S., a biosimilar to Stelara for the ...

In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDItm for all indications matching the reference product Stelara® (ustekinumab) and has granted a provisional determination ...

In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI™ for all indications matching the reference ...

The treatment landscape of Inflammatory Bowel Disease (IBD) has undergone a significant transformation over the past two ...